File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain

TitleSymptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain
Authors
Issue Date2003
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2003, v. 17 n. 3, p. 369-377 How to Cite?
AbstractAim: To determine whether symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Methods: Patients who complained of chest pain, but had normal coronary angiography, were asked to undergo upper endoscopy. Those without gastric and oesophageal lesions were recruited for 24-h ambulatory oesophageal pH monitoring, and were randomly given lansoprazole 30 mg or placebo, both daily for 4 weeks. Chest pain symptoms were recorded before and 1 month after treatment on a locally validated questionnaire. The symptom score was calculated by multiplying the severity and frequency of the symptom, and symptom improvement was defined as >50% reduction in symptom score. Results: Overall, 68 patients, 36 on lansoprazole and 32 on placebo, completed the trial. The symptom score was reduced significantly in both groups (P < 0.001). In the lansoprazole group, more patients with than without abnormal reflux showed symptom improvement (92% vs. 33%; odds ratio = 22; 95% confidence interval, 2.3-201.8: χ2 = 10.9; P = 0.001), giving a sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 92%, 67%, 58%, 94% and 75%, respectively. In the placebo group, the rates of symptom improvement were similar between those with and without abnormal reflux (33% vs. 35%, P = N.S.). Conclusions: Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain.
Persistent Identifierhttp://hdl.handle.net/10722/76886
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorWong, NYHen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorLau, CPen_HK
dc.contributor.authorChen, WHen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2010-09-06T07:25:59Z-
dc.date.available2010-09-06T07:25:59Z-
dc.date.issued2003en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2003, v. 17 n. 3, p. 369-377en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76886-
dc.description.abstractAim: To determine whether symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Methods: Patients who complained of chest pain, but had normal coronary angiography, were asked to undergo upper endoscopy. Those without gastric and oesophageal lesions were recruited for 24-h ambulatory oesophageal pH monitoring, and were randomly given lansoprazole 30 mg or placebo, both daily for 4 weeks. Chest pain symptoms were recorded before and 1 month after treatment on a locally validated questionnaire. The symptom score was calculated by multiplying the severity and frequency of the symptom, and symptom improvement was defined as >50% reduction in symptom score. Results: Overall, 68 patients, 36 on lansoprazole and 32 on placebo, completed the trial. The symptom score was reduced significantly in both groups (P < 0.001). In the lansoprazole group, more patients with than without abnormal reflux showed symptom improvement (92% vs. 33%; odds ratio = 22; 95% confidence interval, 2.3-201.8: χ2 = 10.9; P = 0.001), giving a sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 92%, 67%, 58%, 94% and 75%, respectively. In the placebo group, the rates of symptom improvement were similar between those with and without abnormal reflux (33% vs. 35%, P = N.S.). Conclusions: Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAnti-Ulcer Agents - diagnostic use - therapeutic useen_HK
dc.subject.meshChest Pain - drug therapy - etiology - physiopathologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGastroesophageal Reflux - complications - diagnosis - physiopathologyen_HK
dc.subject.meshGastroscopy - methodsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHydrogen-Ion Concentrationen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - analogs & derivatives - diagnostic use - therapeutic useen_HK
dc.subject.meshPredictive Value of Testsen_HK
dc.subject.meshProspective Studiesen_HK
dc.titleSymptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest painen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=17&spage=369&epage=377&date=2003&atitle=Symptomatic+Response+to+Lansoprazole+Predicts+Abnormal+Acid+Reflux+in+Endoscopy-Negative+Patients+with+Non-Cardiac+Chest+Painen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2003.01436.xen_HK
dc.identifier.pmid12562449-
dc.identifier.scopuseid_2-s2.0-0037328155en_HK
dc.identifier.hkuros80387en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037328155&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue3en_HK
dc.identifier.spage369en_HK
dc.identifier.epage377en_HK
dc.identifier.isiWOS:000180800600008-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridWong, NYH=7202836655en_HK
dc.identifier.scopusauthoridHui, WM=7103196477en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK
dc.identifier.scopusauthoridChen, WH=7409637978en_HK
dc.identifier.scopusauthoridChan, CK=7404813824en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats